Bemarituzumab is a Monoclonal Antibody owned by Amgen, and is involved in 11 clinical trials, of which 5 were completed, 5 are ongoing, and 1 is planned.
Bemarituzumab is a fibroblast growth factor receptor 2b (FGFR2b) antagonist. The FGFR2b protein spans the cell membrane, so that one end of the protein remains inside the cell and the other end projects from the outer surface of the cell. This positioning allows the FGFR2b protein to interact with specific growth factors outside the cell and to receive signals that help the cell respond to its environment. FPA-144 binds to the FGFR2b protein and prevents the cascade of chemical reactions inside the cell that instruct the cell to undergo certain changes such as cell proliferation. This can result in antiproliferative and pro-apoptotic effects. The drug candidate also drive immune-based killing of tumor cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and the recruitment of natural killer (NK) cells and T cells.
The revenue for Bemarituzumab is expected to reach a total of $12.5bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bemarituzumab NPV Report.
Bemarituzumab [FPA-144] is under development for the treatment of solid tumors such as gastric cancer, gastroesophageal cancer, transitional cell carcinoma, lymphoma, bladder cancer, head and neck squamous cell carcinoma, lung adenocarcinoma, fallopian tube cancer, peritoneal cancer, esophageal squamous cell carcinoma, triple-negative breast cancer, pancreatic ductal adenocarcinoma, intrahepatic cholangiocarcinoma, colorectal adenocarcinoma, ovarian epithelial cell carcinoma, endometrial adenocarcinoma and cervical carcinoma. The drug candidate is administered through intravenous route. It is a humanized monoclonal antibody directed against a splice form of fibroblast growth factor receptor 2 (FGFR2). It is a targeted immunotherapy for FGFR2b-overexpressing tumors and designed to recruit tumor-killing NK cells into the tumor microenvironment. The drug candidate is developed based on Potelligent CHOK1SV technology. Potelligent CHOK1SV, combines the advantages of GS Gene Expression System with the glyco-engineered technology.
It was also under development for the treatment of breast cancer.
Zai Lab Overview
Zai Lab biopharmaceutical company that carries out drug development, discovery and commercializing therapies which address medical conditions with unmet needs in oncology. The company offering products pipeline includes Zejula Niraparib is a once-daily small molecule poly (ADP-ribose) polymerase 1/2inhibitor, Optune Tumor Treating Fields for cancer treatment, Qinlock Ripretinib and NUZYRA Omadacycline, a novel tetracycline-class antibacterial. The company market its products to the United States, Europe, Canada, Australia, Greater China and certain other countries and regions. Zai Lab is headquartered in Shanghai, China.
The company reported revenues of (US Dollars) US$144.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$49 million in FY2020. The operating loss of the company was US$700.1 million in FY2021, compared to an operating loss of US$301.8 million in FY2020. The net loss of the company was US$704.5 million in FY2021, compared to a net loss of US$268.9 million in FY2020. The company reported revenues of US$57.5 million for the third quarter ended September 2022, an increase of 19.4% over the previous quarter.
Quick View – Bemarituzumab
|Highest Development Stage|